The Korean journal of internal medicine

  • 제29권6호
  • /
  • Pages.785-792
  • /
  • 2014
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Clinical significance of nuclear factor ${\kappa}B$ and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy

  • Shin, Ho Cheol (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Seo, Jongwon (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Kang, Byung Woog (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Moon, Joon Ho (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Chae, Yee Soo (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Lee, Soo Jung (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Lee, Yoo Jin (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Han, Seoae (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Seo, Sang Kyung (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Kim, Jong Gwang (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Sohn, Sang Kyun (Department of Hematology and Oncology, Kyungpook National University Hospital) ;
  • Park, Tae-In (Department of Pathology, Kyungpook National University Hospital)
  • 투고 : 2013.05.05
  • 심사 : 2014.01.06
  • 발행 : 2014.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: This study investigated the expression of nuclear factor ${\kappa}B$ (NF-${\kappa}B$) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy. Methods: Seventy patients with DLBCL and treated with rituximab-CHOP (R-CHOP) were included, and immunohistochemistry was performed to determine the expression of NF-${\kappa}B$ ($I{\kappa}B$ kinase ${\alpha}$, p50, and p100/p52) and CXCR4. To classify DLBCL cases as germinal center B-cell-like (GCB) and non-GCB, additional immunohistochemical expression of CD10, bcl-6, or MUM1 was used in this study. The expression was divided into two groups according to the intensity score (negative, 0 or 1+; positive, 2+ or 3+). Results: The median age of the patients was 66 years (range, 17 to 87), and 58.6% were male. Twenty-seven patients (38.6%) had stage III or IV disease at diagnosis. Twenty-three patients (32.9%) were categorized as high or high-intermediate risk according to their International Prognostic Indexs (IPIs). The overall incidence of bone marrow involvement was 5.7%. Rates of positive NF-${\kappa}B$ and CXCR4 expression were 84.2% and 88.6%, respectively. High NF-${\kappa}B$ expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression. However, the expression of NF-${\kappa}B$ or CXCR4 was not associated with overall survival and EFS. On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-${\kappa}B$ or CXCR4 expression and survival was observed. Conclusions: The current study suggests that the tissue expression of NF-${\kappa}B$ and CXCR4 may not be an independent prognostic marker in DLBCL patients treated with R-CHOP.

키워드

과제정보

연구 과제 주관 기관 : Kyungpook National University

참고문헌

  1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. https://doi.org/10.1056/NEJMoa011795
  2. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282. https://doi.org/10.1182/blood-2003-05-1545
  3. Kwak JY. Treatment of diffuse large B cell lymphoma. Korean J Intern Med 2012;27:369-377. https://doi.org/10.3904/kjim.2012.27.4.369
  4. Pavan A, Spina M, Canzonieri V, Sansonno S, Toffoli G, De Re V. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008;49:2048-2058. https://doi.org/10.1080/10428190802444176
  5. Johnson PW. New targets for lymphoma treatment. Ann Oncol 2008;19 Suppl 4:iv56-iv59.
  6. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65:264-276.
  7. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707.
  8. Bavi P, Uddin S, Bu R, et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol 2011;224:355-366. https://doi.org/10.1002/path.2864
  9. Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010;341:173-191.
  10. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-3112.
  11. Okera M, Bae K, Bernstein E, et al. Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int 2011;108(2 Pt 2):E51-E58. https://doi.org/10.1111/j.1464-410X.2010.09884.x
  12. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-21638. https://doi.org/10.1074/jbc.M300609200
  13. Scupoli MT, Donadelli M, Cioffi F, et al. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica 2008;93:524-532. https://doi.org/10.3324/haematol.12098
  14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994. https://doi.org/10.1056/NEJM199309303291402
  15. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-376. https://doi.org/10.3322/canjclin.55.6.368
  16. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. https://doi.org/10.1200/JCO.2006.09.2403
  17. Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803-1811. https://doi.org/10.1200/JCO.2010.33.3252
  18. Espinosa I, Briones J, Bordes R, et al. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 2008;53:441-449. https://doi.org/10.1111/j.1365-2559.2008.03139.x
  19. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874. https://doi.org/10.1084/jem.194.12.1861
  20. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-721. https://doi.org/10.1038/nature07968
  21. Saito B, Shiozawa E, Usui T, et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007;21:2563-2566. https://doi.org/10.1038/sj.leu.2404844
  22. Ahn JY, Seo K, Weinberg OK, Arber DA. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol 2013;21:79-84.
  23. Yao X, Zhou L, Han S, Chen Y. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res 2011;39:1253-1264. https://doi.org/10.1177/147323001103900413
  24. Sekiya R, Kajiyama H, Sakai K, et al. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum Pathol 2012;43:904-910. https://doi.org/10.1016/j.humpath.2011.08.002
  25. Jung SJ, Kim CI, Park CH, et al. Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J Urol 2011;52:607-611. https://doi.org/10.4111/kju.2011.52.9.607

피인용 문헌

  1. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in as vol.28, pp.9, 2014, https://doi.org/10.1038/modpathol.2015.76
  2. Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin vol.142, pp.11, 2014, https://doi.org/10.1007/s00432-016-2220-6
  3. Modeling the Pro-inflammatory Tumor Microenvironment in Acute Lymphoblastic Leukemia Predicts a Breakdown of Hematopoietic-Mesenchymal Communication Networks vol.7, pp.None, 2014, https://doi.org/10.3389/fphys.2016.00349
  4. The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines vol.4, pp.1, 2014, https://doi.org/10.1186/s40364-016-0067-2
  5. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma vol.59, pp.6, 2018, https://doi.org/10.1080/10428194.2017.1379077
  6. High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients vol.10, pp.7, 2019, https://doi.org/10.18632/oncotarget.26588
  7. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights vol.15, pp.12, 2014, https://doi.org/10.2217/fon-2018-0514
  8. CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression vol.185, pp.5, 2014, https://doi.org/10.1111/bjh.15670
  9. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges vol.142, pp.2, 2014, https://doi.org/10.1159/000497430
  10. The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro vol.20, pp.19, 2014, https://doi.org/10.3390/ijms20194740
  11. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels vol.38, pp.1, 2019, https://doi.org/10.1186/s13046-019-1081-7